CDMO News
Johnson & Johnson and Legend Biotech Expand Manufacturing Deal with Novartis
Johnson & Johnson and Legend Biotech have announced the expansion of their partnership with Novartis to manufacture their multiple myeloma treatment, CAR-T Caryvkti until the end of 2029. The deal will see Novartis supply Carvykti from its cell therapy site in
29 March 2024
Stay ahead of trends and best practices
